Klivira
Request demo

Streamlining Medicare Rexulti Prior Authorization

Navigating Medicare Rexulti prior authorization presents unique challenges, particularly given the drug's common PA requirements and Medicare's specific administrative structures for medical and pharmacy benefits. Klivira provides the automation needed to manage this complexity.

Revenue cycle teams and prior authorization coordinators face a complex landscape when managing high-volume medications like Rexulti for Medicare beneficiaries. Understanding the distinct processes for Original Medicare (Part A/B) and Medicare Part D is critical for efficient PA submission and approval, ensuring timely patient access to essential treatments.

Rexulti and Prior Authorization in the Medicare Context

Rexulti (brexpiprazole) is an atypical antipsychotic indicated for schizophrenia and as adjunctive treatment for major depressive disorder. Due to its therapeutic class and cost, Rexulti is a high-volume prior authorization target across various payer types, including Medicare Advantage and Medicaid managed care plans. For Medicare beneficiaries, PA requirements are primarily managed under Medicare Part D, which covers prescription drugs.

Understanding Medicare's Prior Authorization Framework for Drugs

Original Medicare (Parts A and B) has limited prior authorization scope, primarily for specific medical services and durable medical equipment, with submissions routing through Medicare Administrative Contractors (MACs) such as Noridian, NGS, WPS, Palmetto, FCSO, and Novitas. For prescription drugs like Rexulti, prior authorization falls under Medicare Part D. Part D plans, operated by private commercial insurers, administer pharmacy PA per CMS-approved plan formularies and step-therapy protocols.

Policy Access and Guidelines for Medicare Drug PAs

While National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) published by MACs govern medical services under Original Medicare, drug-specific PA criteria for Part D are defined by the individual Part D plans. These criteria must align with CMS-approved formularies, step-therapy requirements, and quantity limits. Klivira's platform incorporates logic to navigate these varied policy sources, ensuring submissions are aligned with the payer's specific requirements.

Submission Channels for Medicare Rexulti Prior Authorization

For Rexulti, PA requests are typically submitted to the patient's Medicare Part D plan or its designated Pharmacy Benefit Manager (PBM). Klivira's robust connectivity facilitates electronic prior authorization (ePA) submissions to a broad network of Part D plans, streamlining what can often be a manual and time-consuming process. While Traditional Medicare medical PA (e.g., for Outpatient Department services or DME) routes through MAC-specific channels, drug PAs are distinct.

Klivira's Approach to Medicare Drug Prior Authorization

Klivira automates the complex workflows associated with Medicare Rexulti prior authorization. Our platform integrates with your EMR system, leveraging SMART on FHIR standards where applicable, to extract necessary clinical data. We then intelligently route PA requests to the appropriate Medicare Part D plan or PBM, ensuring adherence to their specific submission channels and policy requirements. This reduces manual effort, accelerates turnaround times, and minimizes potential denials.

Frequently asked questions

Does Original Medicare (Part A/B) require prior authorization for Rexulti?

No, prior authorization for prescription drugs like Rexulti is primarily managed under Medicare Part D. Original Medicare's PA scope is limited to specific medical services and durable medical equipment.

How do Medicare Advantage plans handle Rexulti prior authorization?

Medicare Advantage (MA) plans, which are private plans, administer prior authorizations for drugs like Rexulti according to their specific formularies, medical policies, and utilization management criteria, similar to commercial plans. Klivira supports PA submissions for MA plans.

What role do NCDs and LCDs play in Rexulti prior authorization?

National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) establish coverage criteria for medical services under Original Medicare. For prescription drugs under Part D, PA criteria are set by individual Part D plans, aligning with CMS-approved formularies, rather than NCDs or LCDs.

How does Klivira support Medicare Part D prior authorizations for drugs like Rexulti?

Klivira integrates with your EMR to gather clinical data and electronically submits prior authorization requests directly to Medicare Part D plans and their associated PBMs. Our system ensures submissions meet plan-specific formulary, step-therapy, and documentation requirements.

What are common challenges for Rexulti prior authorization under Medicare?

Challenges include navigating the specific formulary and step-therapy requirements of individual Part D plans, ensuring complete clinical documentation to support medical necessity, and managing the varying submission portals and processes across different plans. Klivira addresses these by centralizing and automating the workflow.

Related coverage

Other rexulti prior authorization by payer

Other rexulti prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo